Lisa Ricciardi

► CONTRAFECT (NASDAQ: CFRX) 2016 – 2017 Developing first-in-class therapies for drug resistant, life-threatening infections. Member, Board of Directors; Compensation, Nomination & Governance Committees ► CHIMERIX, (NASDAQ: CMRX) 2014 – 2017 Biopharmaceutical company focused on antivirals in areas of unmet medical need. Member, Board of Directors; Chair, Compensation Committee ► UNITED DRUG HEALTHCARE GROUP, PLC, (LSE: UDG) 2013 – Present International provider of services to healthcare manufacturers and pharmaceutical retailers. Member, Board of Directors; Risk/Acquisition/Finance, Compensation Committees ► SEPRACOR, (NASDAQ: SEPR) 2007 – 2009 Specialty pharmaceutical company focusing on respiratory and central nervous system. Member, Board of Directors; Compensation Committee Member, Special Committee, Company Sale to Dainippon Sumitomo Pharma ($2.6B closed October, 2009)

Grew company from a single- to multi-platform therapeutic model and created the strategic plan to expand clinical trials of lead therapeutic for Alzheimer’s disease to encompass indications for other CNS disorders. In October 2021 completed oversubscribed IPO raising $48M to fund clinical trials, discovery and operations ►Partnered with executive leadership team to create narrative for investment community to secure funding for the creation and clinical development of a pipeline of disease-modifying drug candidates for the treatment of neurological disease. ►Manage relationships with VC and investor syndicates and foundation partners specializing in healthcare, technology, and innovation investments to communicate funding and capital allocation strategy. ► Identified advisory team to support clinical trials across several CNS disorders, including Alzheimer’s Parkinson’s, ALS, and AMD.

Partner with entrepreneurs and inventors at Columbia University to facilitate the transfer of research innovations from the lab to the market, as well as supporting start-up efforts.

For this Polaris VC-backed medical device start-up, created roadmap for product commercialization by leveraging strong relationships in biotech and pharma and building financial, operational, and governance infrastructure. ► Refined product value proposition and engaged strategic partner in long-term sales process with forecast for a US commercialization.

Tapped for interim operating executive and advisory board roles. ► Negotiated deal on behalf of a specialized pharmacy with pharmaceutical partners in the dialysis category, driving 90% of EBITDA. ► Created a financial platform for regenerative medicine company to complete Phase II clinical trials.

Hired to drive revenue for molecular information and diagnostic test company through pharma and commercialization deals. ► Led an industry-recognized $1.03B aggregate investment with Roche to develop five transformative immunology, biomarker, and companion diagnostic test development products. ► Closed first-of-the-kind deals with partners to productize data to market subscription-based services and leverage FMI data to deliver solutions for treatments and clinical trials. ► Signed inaugural exclusive distribution and licensing agreement with a global pharmaceutical, biopharmaceutical, and medical device company to provide genomic testing services in China with WuXi.

Oversaw worldwide expansion initiatives and evaluated small-to-multibillion-dollar deals: HCIT, CROs, onsite clinics, oncology, obesity, and lab services. ► Co-negotiated the $29B company sale to Express Scripts, creating the largest pharmacy benefits management company in the US. ► Developed a multimillion-dollar strategic partnership introducing pharmacy medical benefits best practices to a medical benefits program. ► Led a restructuring initiative to elevate talent while cutting costs.

► Tapped to identify investment opportunities, conduct due diligence, and prepare investment memorandums. Enhanced sale processes by creating pharma-caliber marketing, research, forecasts, and communication decks.

Personally recruited by Chairman/CEO to create new licensing and development division. Led evaluation, licensing, and negotiations for global deals. Represented Pfizer at biotech, investor, and banking conferences. ► Completed 25+ deals representing ~50% of pipeline. Doubled volume of exploratory meetings and increased new leads by 50%.

► Led Zithromax, Trovan, and Norvasc launches against internal and external competitors. Hand-picked to launch Tenidap, a novel drug that was expected to become Pfizer’s largest product.